ArticleACS omega2025
Probing Antimicrobial Activity and Mechanism of Action of a Bile Acid-Derived Antibiotic.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antibiotics have revolutionized medicine, saving countless lives since the introduction of penicillin. However, antimicrobial resistance has challenged their efficacy, prompting ongoing efforts to develop new antibiotics. This study explores the antimicrobial effects of a bile acid derivative, BA-3/4-Butyl. By analyzing the interactions of BA-3/4-Butyl with model bacterial (DOPC/DOPG) and mammalian (DOPC/cholesterol) membranes and by probing its mechanism of action against bacteria using a variety of assays and transmission electron microscopy (TEM) imaging, we reveal that BA-3/4-Butyl exerts its antimicrobial activity via membrane permeabilization. Our findings provide insights into how BA-3/4-Butyl compromises bacterial membranes without causing toxicity in its mammalian counterparts. This study advances the understanding of BA-3/4-Butyl's antimicrobial activity and potential mechanisms of action, ultimately aiding the development of similar novel therapeutic agents to help combat antimicrobial resistance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.